Researcher:
Kılıç, Lütfiye

Profile Picture
ORCID

Job Title

Doctor

First Name

Lütfiye

Last Name

Kılıç

Name

Name Variants

Kılıç, Lütfiye

Email Address

Birth Date

Filters

2022 - 20233

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.9b875a78-ea91-4b16-b9c8-f36afa9aba49

Search Results

Now showing 1 - 3 of 3
  • Placeholder
    PublicationMetadata only
    Management of polydrug-resistant tuberculosis
    (MDPI, 2023) Ortakoylu, Mediha Gonenc; Kibar Akilli, Isil; Akbaba Bagci, Belma; Akalin, Esma Seda; Aksan, Arzu Deniz; Toprak, Sezer; Mirsaeidi, Mehdi; N/A; Kılıç, Lütfiye; Doctor; N/A; Koç University Hospital; N/A
    Background and Objectives: There is a lack of information regarding the effective duration of treatment necessary to prevent the development of acquired resistance when fluoroquinolones (FQ), and/or pyrazinamide (Z) resistance has occurred in patients with polydrug-resistant tuberculosis and isoniazid resistance. The management of these kinds of patients should be carried out in experienced centers according to drug susceptibility test results, clinical status of the patient and the extensity of the disease. Materials and Methods: We evaluated treatment regimens, treatment outcomes, and drug adverse effects in seven patients with polydrug-resistant tuberculosis, including those with Z and/or FQ resistance in a retrospective analysis Results: Regarding the patients with polydrug-resistant tuberculosis in addition to isoniazid (H) resistance, three had Z, two had FQ, and the remaining two had both Z and FQ resistance. In the intensive phase of the treatment, the patients were given at least four drugs according to drug susceptibility tests, and at least three drugs in the continuation phase. The duration of treatment was 9–12 months. Two of the patients were foreign nationals, and could not be followed up with due to returning to their home countries. Regarding the remaining five patients, three of them were terminated as they completed treatment, and two as cured. No recurrence was observed in the first year of the treatment. The most common, and serious drug side effect was seen for amikacin. Conclusions: In patients with polydrug-resistant TB, if Z and/or FQ resistance is detected in addition to H resistance, the treatment of these patients should be conducted on a case-by-case basis, taking into account the patient’s resistance pattern, clinical condition, and disease prognosis. Close monitoring of the side effects will increase the success rate of the treatment.
  • Placeholder
    PublicationMetadata only
    The relationship between functional status and fatigue after COVID-19 infection
    (European Respiratory Society (ERS), 2022) Candemir, I. Cayli; Ergun, P.; Kaymaz, D.; Ozmen, I; Yildirim, E.; Dilektasli, A. Gorek; Yigitler, B.; Kizilirmak, D.; Sari, S.; Korkmaz, C.; Tasci, C.; Arslan, Y.; Savci, S.; Kahraman, B.; Tanriverdi, A.; Sevinc, C.; Saglam, M.; Ince, D. Inal; Yagli, N. Vardar; Kutukcu, E.; Durmaz, D.; Duruturk, N.; Ulubay, G.; Moray, A.; Olcay, S. S.; N/A; Kılıç, Lütfiye; Çağlar, Barış; Doctor; Faculty Member; N/A; School of Medicine; Koç University Hospital; N/A; N/A; N/A
    N/A
  • Thumbnail Image
    PublicationOpen Access
    Co-infection of COVID-19 and tuberculosis
    (Aves, 2022) Altın, S.; Gönenç Ortaköylü, M.; Kanmaz, Z.D.; Tutar, T.; Özkan G.Z.; Kılıç, Lütfiye; Faculty Member; Koç University Hospital
    Objective: Tuberculosis and COVID-19 diseases occur more frequently in people with similar risk factors. This study aimed to share the data on active tuberculosis patients during the severe acute respiratory syndrome coronavirus 2 pandemic. Material and methods: The registration information of TB outpatient clinic between November 1, 2019, and April 20, 2020, was screened. A 7-question survey was administered to the patients who were diagnosed with active tuberculosis and who were agreed to participate in the study. Results: A total of 309 patients with active tuberculosis were evaluated, the average age of the patients was 42.5 ± 18.5 years, and 70% were male. The percentage of having at least 1 comorbidity was 30.4%. The percentage of coronavirus disease 2019 disease in our study population was 1.9%; none of the patients of coronavirus disease 2019 were taken into the intensive care unit or dead due to clinical deterioration and/or respiratory failure. On the other hand, in this process it was announced that 146 457 cases were diagnosed with coronavirus disease 2019 throughout the country, of which 72% had inpatient treatment, 2% died, and 944 patients were still being treated in the intensive care unit, of which 490 were intubated. The positivity ratio of the reverse transcription-polymerase chain reaction test was 20.0% in the study group, while 20.3% in the İstanbul population. Conclusion: Tuberculosis patients might be more disadvantageous than the normal population in terms of the risk of exposure to severe acute respiratory syndrome coronavirus 2, but this does not cause an increase in the frequency and severity of coronavirus disease 2019 disease in active tuberculosis patients.